β2 AR Agonists in Treatment of Chronic Heart Failure: Long Path to Translation

Mark I. Talan, Ismayil Ahmet, Riu Ping Xiao, Edward Lakatta

Research output: Contribution to journalReview article

Abstract

The main clinical manifestations of advanced chronic heart failure (CHF), e.g. in dilated cardiomyopathy (DCM), are reduced systolic and diastolic functions, increased arterial elastance and arterio-ventricular uncoupling, accompanied and exacerbated by an excessive sympathetic activation and extensive abnormalities in the βAR signaling. Loss of cardiomyocytes due to apoptosis is one mechanism that undoubtedly contributes to cardiac remodeling and functional deterioration associated with dilated cardiomyopathy (DCM). Research during the last decade on the single cardiomyocyte level strongly suggested that selective stimulation of β1 AR activates the proapoptotic signaling pathways, while selective stimulation of β2 AR is antiapoptotic, but its precise mechanisms remain to be elucidated. Extensive research in the rat model of DCM following induction of myocardial infarction (MI) showed that prolonged treatment with of β2 AR agonist, fenoterol, in combination with a β1 AR blocker, metoprolol, is more effective than β1 AR blocker alone and as effective as β1 AR blocker with ACE inhibitor with respect to survival and cardiac remodeling. This combined regimen of β2 AR agonists and a β1 AR blocker might be considered for clinical testing as alternative or adjunct therapy to currently acceptable CHF arsenal. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure".

Original languageEnglish (US)
Pages (from-to)529-533
Number of pages5
JournalJournal of Molecular and Cellular Cardiology
Volume51
Issue number4
DOIs
StatePublished - Oct 2011
Externally publishedYes

Fingerprint

Heart Failure
Dilated Cardiomyopathy
Cardiac Myocytes
Fenoterol
Metoprolol
Research
Angiotensin-Converting Enzyme Inhibitors
Hypertrophy
Myocardial Infarction
Amberlite XAD-2 resin
Apoptosis
Therapeutics

Keywords

  • β adrenergic receptor gonists
  • Beta adrenergic receptors
  • Cardiac remodeling
  • Chronic heart failure

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

β2 AR Agonists in Treatment of Chronic Heart Failure : Long Path to Translation. / Talan, Mark I.; Ahmet, Ismayil; Xiao, Riu Ping; Lakatta, Edward.

In: Journal of Molecular and Cellular Cardiology, Vol. 51, No. 4, 10.2011, p. 529-533.

Research output: Contribution to journalReview article

Talan, Mark I. ; Ahmet, Ismayil ; Xiao, Riu Ping ; Lakatta, Edward. / β2 AR Agonists in Treatment of Chronic Heart Failure : Long Path to Translation. In: Journal of Molecular and Cellular Cardiology. 2011 ; Vol. 51, No. 4. pp. 529-533.
@article{c21840b57a7640cfbbdb883771b9b178,
title = "β2 AR Agonists in Treatment of Chronic Heart Failure: Long Path to Translation",
abstract = "The main clinical manifestations of advanced chronic heart failure (CHF), e.g. in dilated cardiomyopathy (DCM), are reduced systolic and diastolic functions, increased arterial elastance and arterio-ventricular uncoupling, accompanied and exacerbated by an excessive sympathetic activation and extensive abnormalities in the βAR signaling. Loss of cardiomyocytes due to apoptosis is one mechanism that undoubtedly contributes to cardiac remodeling and functional deterioration associated with dilated cardiomyopathy (DCM). Research during the last decade on the single cardiomyocyte level strongly suggested that selective stimulation of β1 AR activates the proapoptotic signaling pathways, while selective stimulation of β2 AR is antiapoptotic, but its precise mechanisms remain to be elucidated. Extensive research in the rat model of DCM following induction of myocardial infarction (MI) showed that prolonged treatment with of β2 AR agonist, fenoterol, in combination with a β1 AR blocker, metoprolol, is more effective than β1 AR blocker alone and as effective as β1 AR blocker with ACE inhibitor with respect to survival and cardiac remodeling. This combined regimen of β2 AR agonists and a β1 AR blocker might be considered for clinical testing as alternative or adjunct therapy to currently acceptable CHF arsenal. This article is part of a special issue entitled {"}Key Signaling Molecules in Hypertrophy and Heart Failure{"}.",
keywords = "β adrenergic receptor gonists, Beta adrenergic receptors, Cardiac remodeling, Chronic heart failure",
author = "Talan, {Mark I.} and Ismayil Ahmet and Xiao, {Riu Ping} and Edward Lakatta",
year = "2011",
month = "10",
doi = "10.1016/j.yjmcc.2010.09.019",
language = "English (US)",
volume = "51",
pages = "529--533",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - β2 AR Agonists in Treatment of Chronic Heart Failure

T2 - Long Path to Translation

AU - Talan, Mark I.

AU - Ahmet, Ismayil

AU - Xiao, Riu Ping

AU - Lakatta, Edward

PY - 2011/10

Y1 - 2011/10

N2 - The main clinical manifestations of advanced chronic heart failure (CHF), e.g. in dilated cardiomyopathy (DCM), are reduced systolic and diastolic functions, increased arterial elastance and arterio-ventricular uncoupling, accompanied and exacerbated by an excessive sympathetic activation and extensive abnormalities in the βAR signaling. Loss of cardiomyocytes due to apoptosis is one mechanism that undoubtedly contributes to cardiac remodeling and functional deterioration associated with dilated cardiomyopathy (DCM). Research during the last decade on the single cardiomyocyte level strongly suggested that selective stimulation of β1 AR activates the proapoptotic signaling pathways, while selective stimulation of β2 AR is antiapoptotic, but its precise mechanisms remain to be elucidated. Extensive research in the rat model of DCM following induction of myocardial infarction (MI) showed that prolonged treatment with of β2 AR agonist, fenoterol, in combination with a β1 AR blocker, metoprolol, is more effective than β1 AR blocker alone and as effective as β1 AR blocker with ACE inhibitor with respect to survival and cardiac remodeling. This combined regimen of β2 AR agonists and a β1 AR blocker might be considered for clinical testing as alternative or adjunct therapy to currently acceptable CHF arsenal. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure".

AB - The main clinical manifestations of advanced chronic heart failure (CHF), e.g. in dilated cardiomyopathy (DCM), are reduced systolic and diastolic functions, increased arterial elastance and arterio-ventricular uncoupling, accompanied and exacerbated by an excessive sympathetic activation and extensive abnormalities in the βAR signaling. Loss of cardiomyocytes due to apoptosis is one mechanism that undoubtedly contributes to cardiac remodeling and functional deterioration associated with dilated cardiomyopathy (DCM). Research during the last decade on the single cardiomyocyte level strongly suggested that selective stimulation of β1 AR activates the proapoptotic signaling pathways, while selective stimulation of β2 AR is antiapoptotic, but its precise mechanisms remain to be elucidated. Extensive research in the rat model of DCM following induction of myocardial infarction (MI) showed that prolonged treatment with of β2 AR agonist, fenoterol, in combination with a β1 AR blocker, metoprolol, is more effective than β1 AR blocker alone and as effective as β1 AR blocker with ACE inhibitor with respect to survival and cardiac remodeling. This combined regimen of β2 AR agonists and a β1 AR blocker might be considered for clinical testing as alternative or adjunct therapy to currently acceptable CHF arsenal. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure".

KW - β adrenergic receptor gonists

KW - Beta adrenergic receptors

KW - Cardiac remodeling

KW - Chronic heart failure

UR - http://www.scopus.com/inward/record.url?scp=80052792976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052792976&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2010.09.019

DO - 10.1016/j.yjmcc.2010.09.019

M3 - Review article

C2 - 20888833

AN - SCOPUS:80052792976

VL - 51

SP - 529

EP - 533

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

IS - 4

ER -